On the Record · Vertex Pharmaceuticals Inc / MA

Vertex Pharmaceuticals Inc / MA acquisitions, on the record

The businesses Vertex Pharmaceuticals Inc / MA bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Semma Therapeutics, Inc. Word for word“In 2019, we acquired Semma Therapeutics, Inc., pursuant to which we established our T1D program, and Exonics Therapeutics, Inc., which enhanced our gene-editing capabilities to repair mutations that cause severe neuromuscular diseases, such as DM1 and Duchenne muscular dystrophy.” 10-K for 2023	acquisition	In 2019	—
Exonics Therapeutics, Inc. Word for word“In 2019, we acquired Semma Therapeutics, Inc., pursuant to which we established our T1D program, and Exonics Therapeutics, Inc., which enhanced our gene-editing capabilities to repair mutations that cause severe neuromuscular diseases, such as DM1 and Duchenne muscular dystrophy.” 10-K for 2023	acquisition	In 2019	—
ViaCyte, Inc. Word for word“In 2022, we acquired ViaCyte, Inc. (“ViaCyte”), which had intellectual property, tools, technologies and assets with the potential to accelerate development of our T1D programs.” 10-K for 2023	acquisition	In 2022	—
Catalyst's complement portfolio Word for word“AIPR&D in 2022 was primarily related to the $60.0 million payment to acquire Catalyst’s complement portfolio, a $25.0 million upfront payment pursuant to our license agreement with Verve, and various other payments.” 10-K for 2023	acquisition	2022	$60.0 million
novel GPCR program from Septerna Word for word“AIPR&D in 2023 was primarily related to our $225.1 million upfront payment to Entrada, $100.0 million upfront 75 payment and $70.0 million T1D research milestone to CRISPR, $47.5 million acquisition of a novel GPCR program from Septerna, and various other payments.” 10-K for 2023	acquisition	2023	$47.5 million
Alpine Immune Sciences, Inc. Word for word“In May 2024, we acquired Alpine for approximately $5.0 billion.” 10-K for 2024	acquisition	In May 2024	approximately $5.0 billion
Concert Pharmaceuticals Inc. (certain CF assets, including deutivacaftor) Word for word“In 2017, we enhanced our CF portfolio through our acquisition of certain CF assets, including deutivacaftor, from Concert Pharmaceuticals Inc.” 10-K for 2024	acquisition	In 2017	—
Septerna (novel GPCR program) Word for word“In 2023, AIPR&D consisted of our $225.1 million upfront payment to Entrada, $100.0 million upfront payment and $70.0 million T1D research milestone to CRISPR, $47.5 million acquisition of a novel GPCR program from Septerna, and various other payments.” 10-K for 2024	acquisition	In 2023	$47.5 million

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)
2017-12-31	$0
2018-12-31	$0
2019-12-31	$1.15 billion
2020-12-31	$0
2021-12-31	$0
2022-12-31	$295.9 million
2023-12-31	$0
2024-12-31	$0

Deal filings since 2016

2026-07-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-08-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-04-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-07-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-04-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-09-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-09-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-09-03 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-06-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-05-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-10-27 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2017-10-25 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2017-06-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-03-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-01-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-10-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2016-10-14 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Vertex Pharmaceuticals Inc / MA’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-13. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.